The species cannabis sativa L. is composed of sativa, indica and ruderalis; each has distinct characteristics. Cannabis sativa can grow to heights exceeding 10-feet and is consumed for its head-effects including energy and creative thinking. Cannabis indica is a shorter, bushier plant and is consumed for its body-effects including pain and insomnia. Cannabis ruderalis produces much less of the phytocannabinoid delta-9-tetrahydrocannabinol (Δ9-THC or THC) and may be combined with sativa or indica to produce hybrid strains.

Hemp is cannabis. The tall fibrous hemp plant is known for its naturally abundant non-psychotropic cannabidiol (CBD) production and has more than 25,000 reported uses. Hemp is a versatile plant used in food, health & wellness products, and industrial applications including building materials and alternative fuel. Hemp is legal throughout the U.S. and its territories.


Figure 1: Three Types of Cannabis Photo Credit: Wikipedia

The U.S. National Library of Medicine National Institutes of Health cites, “…the cannabis plant consists of over 400 chemical entities, of which more than 60 of them are phytocannabinoid compounds.”

The legal cannabis market primarily retails THC and CBD. One cannot get “high” from CBD. Hemp is defined as, “…cannabis and cannabis derivatives with very low concentrations (no more than 0.3% on a dry weight basis) of THC.” Some manufacturers isolate the CBD molecule and produce THC-free products.



The organ systems in mammals are respiratory, circulatory, nervous, digestive, endocrine, reproductive, lymphatic, muscular, immune, skeletal, urinary, integumentary and endocannabinoid. The endocannabinoid system was discovered in 1992 and consists of CB1 and CB2 receptors found throughout the body.

A report on the history of the endocannabinoid system discovery states, “Since their discovery, endocannabinoids have been found to play a role in memory, mood, appetite and metabolism, sleep, pain response, thermoregulation and immunity. The system also appears to regulate reproduction; the developing embryo expresses cannabinoid receptors that are responsive to anandamide secreted in the uterus.”

Figure 2: Endocannabinoid Receptors

Working with Veterans and CBD since 1984 is Dr. Jose L. Bautista, an internal medicine physician in Fresno, California. He describes the endocannabinoid system as a regulator of homeostasis in the body.

Dr. Jose L. Bautista states, “The central nervous system is the one that controls everything in the body. So, if you can penetrate the blood-brain barrier all the receptors of the brain will communicate with the rest of the systems and the benefits will be great.”



Types of cannabis products available to consumers range from flower to oil extracts in a variety of forms. There are currently 33 legal medical cannabis and 11 recreational cannabis states.

Digestion of oils and fats take time to process. Oil-based CBD content is partially lost in the digestion process and can take up to two hours to feel the effects. Bioavailability is the term used for how much and at what rate a substance is absorbed in the bloodstream. According to research, the bioavailability scale for CBD is:

  • Vaporizing / Inhaling: 34- 46% (up to 56%), effects felt within 10 minutes

  • Sublingual: 13-19% (up to 35%), effects felt within 5-20 minutes

  • Edibles: 6-20%, effects felt within 30-120 minutes

  • Topicals: low, effects felt within minutes

Fresno, California primary care physician, Juan Bautista, MD specializes in regenerative and functional medicine. Dr. Juan Bautista serves clients from current and former athletes to the elderly. He has studied CBD for four years and for the past two years has suggested to his patients to try CBD. Dr. Bautista’s method is to take a “less is more” approach to CBD to avoid oversaturation of the endocannabinoid receptors in the body.

Dr. Juan Bautista prefers oil-free CBD as a therapeutic delivery method and explains, “By making it a water-based product, it allow us to not saturate the receptors of the eCS therefore not only making it therapeutic but using only the minimal amount that’s needed.” Oversaturation of the CB1 and CB2 receptors can have a detrimental effect on efficacy of other medications that are prescribed, Dr. Juan Bautista explains.



A science breakthrough reveals a new delivery method of oil-free CBD in a water carrier. Combined with curcumin, a component in turmeric, the water-based delivery system is unique.

Scientists in California researched a water-based delivery technology after calculating that, based on body weight, a person would need to ingest more than one kilogram (2.2 pounds) of curcumin per day to maximize health benefits. As a result, the laboratory proceeded to molecularly combine curcumin in a water complex that could be readily absorbed by the body. After successfully binding curcumin in water as a delivery technology, the laboratory researched hemp CBD with curcumin. It, too, was successful.



Recent independent clinical laboratory tests were conducted by Excellence in Mental Wellness using an FDA-approved EEG medical device to track the bioavailability of CBD oil compared to CBD-curcumin complex in a water-based delivery technology. The clinical tests conducted by Excellence in Mental Wellness started by creating a baseline EEG brain scan with an FDA-approved medical device.

Figure 3: FDA-Approved EEG Tests Compare Brain Activity After Consuming 2.5 ml of CBD Oil vs. 2.5 ml of Oil-Free CBD-Curcumin Complex
Photo Credit: Excellence in Mental Wellness

The clinical test baseline EEG scanned brain data for approximately two to three minutes both with eyes open and eyes closed. An EEG displaying red indicates stress, irritation, inflammation, and a dysregulated brain. All test subjects indicated red at this stage of testing.

Figure 4: FDA-Approved EEG Device Tracking Baseline Brain Activity of Test Subjects
Photo Credit: Excellence in Mental Wellness



Excellence in Mental Wellness’ EEG tests continued with administration of 2.5ml of CBD oil consumed sublingually.

Figure 5: EEG Test Subjects Consumed 2.5 ml of CBD Oil Sublingually
Photo Credit: Excellence in Mental Wellness

After as much as 10 minutes, no change in EEG activity is detected with any of the test subjects after consuming 2.5 ml of CBD oil sublingually.

Figure 6: FDA-Approved EEG Device Tracks No EEG Change After Consuming 2.5 ml of CBD Oil. Elapsed Time Approximately 2-10 Minutes.
Photo Credit: Excellence in Mental Wellness

The next phase of EEG testing continued with oral administration of 2.5 ml of oil-free CBD-curcumin complex.

Figure 7: Test Subjects Consume 2.5 ml of Oil-Free, CBD-Curcumin Complex
Photo Credit: Excellence in Mental Wellness

Within two to six minutes, each test subject’s EEG showed a change in color. In all test subjects, the EEG mostly indicated green, a functioning, calmer, stable and regulated brain after consuming the oil-free CBD-curcumin complex. The test administrator explained that outside distractions or having eyes open generates short bursts of yellow, orange or red on the display. The visible change in EEG brain activity (predominantly green) occurred in as little as two minutes compared to no change with CBD oil in as much as ten minutes (red).

Figure 8: FDA-Approved EEG Device Tracks Oil-Free, CBD-Curcumin Complex Crossing Blood-Brain Barrier. Elapsed Time Approximately 2-6 Minutes. Photo Credit: Excellence in Mental Wellness

A continuous video of the EEG tests was taken. The video indicates the duration of each stage of the tests. There is now visible proof that oil-free CBD-curcumin complex crosses the blood brain barrier effectively in comparison to CBD oil. A sample report of the EEG scan below shows one test subject’s before and after results.

Figure 9: Independent Laboratory EEG Results Using an FDA-Approved Medical Device Shows Oil-Free Hemp CBD-Curcumin Complex Crosses the Blood-Brain Barrier and is Rapidly Bioavailable.
Photo Credit: Excellence in Mental Wellness



After witnessing the bioavailability of oil-free CBD-curcumin complex through EEG, a comparison to EEG clinical tests using CBD oil is warranted.

A research study conducted by the University of Alabama documents test subjects that ingested CBD at a maximum of 25 mg/kg of body weight for approximately one month. (For a 120 lb. person, 25 mg/kg of body weight is equivalent to 1,360 mg of CBD per day.)

The University of Alabama research findings state, “Though this initial EEG recording did not show any significant changes after receiving CBD, it is important to note that the results of this initial study are restricted by a relatively short EEG recording time (20 minutes).”

Also, it is important to note that in each 1,200 ml bottle of the oil-free, CBD-curcumin complex is a 1:1 ratio of curcumin:CBD; only 12 mg of each component are required to manufacture a 1,200 ml bottle. In the EEG clinical study by Excellence in Mental Wellness, 2.5 ml was administered followed by visible proof that the oil-free CBD-curcumin complex crosses the blood-brain barrier in as little as two minutes.

This new research data sets a standard for the CBD-curcumin complex as having a “less is more” approach with cannabis consumption. The laboratory that discovered the complex and water delivery technology can also bind other non-bioavailable particles into a water complex to increase bioavailability.

Figure 10: Oil-Free Hemp CBD-Curcumin Complex Consumer Product Line
Photo Credit: BioReigns

The oil-free CBD-curcumin complex used by Excellence in Mental Wellness for the clinical EEG tests was supplied by the exclusive U.S. manufacturer BioReigns.

Dr. Jose L. Bautista states, “When you have a water-soluble compound that can penetrate the blood-brain barrier like water-soluble CBD, you’re going to get the most benefits.”

Both doctors suggest BioReigns products with their patients. Dr. Juan Bautista concludes, “When I see a company like BioReigns, what they’re doing is not badmouthing CBD oil, but rather improving CBD.” Dr. Juan Bautista envisions IV and injectable therapeutic treatments with oil-free CBD in the future of medicine.



Bioavailability proof via the oil-free CBD-curcumin complex is clear and supported by EEG data with an FDA-approved medical device. What can be done with this data? How can this information be shared among the healing community and how can it be useful to physicians globally?

Since 100 AD, the cannabis plant has been documented in healing yet it was removed from the U.S. pharmacopeia in 1942. For purposes of clarifying the cannabis plant has medicinal value, data aggregation is important to the cannabis industry as an ongoing body of public research.

Dr. Helen “Golda” Joseph, Founder of Jade Health, created a web-based SaaS platform that provides a suite of HIPAA and EU GDPR compliant data and technology solutions for clinical, commercial and research applications. The customized platform filters and provides quality information on cannabis products and services to educate consumers, health-care providers, researchers and all stakeholders by leveraging data analytics, biomarkers and human genomics (optional).

The data analysis platform anonymously tracks consumer profiles (age, gender, weight, height), brands & types of products and prescriptions used, product delivery method, strain names, frequency of consumption, laboratory results & test data (ex. EEG, blood, wearable devices) allowing a more customized approach to total wellness.

Had there been a way to easily track and use empirical data for research in the 1940s, perhaps cannabis would have remained in the U.S. pharmacopeia. Since the 1980s, cannabis has slowly been restored to the U.S. at a state level. Today, cannabis is making a global resurgence.



The return of legal cannabis has created a multibillion-dollar global industry. The hemp CBD industry is projected to reach $20 billion by 2024 and the legal “marijuana” industry is now projected to reach $85 billion by 2030. More than half of U.S. states are legally retailing cannabis products that contain THC and hemp products are legal in all 50 states.

With the knowledge that mammals have an endocannabinoid system and are inherently designed to consume cannabis, it is no surprise that the growth of the global cannabis industry is on a skyrocketing trajectory. With the science breakthrough of clinically tested, bioavailable, oil-free, CBD-curcumin complex — and the same method for delivering other phytocannabinoids, oil-based healing compounds, and non-bioavailable materials via water delivery technology — it leads one to believe that these cannabis industry financial projections may soon be adjusted to reflect additional consumer demand.